cyclic
adenosin
monophosph
camp
univers
second
messeng
upon
interact
evolutionarili
conserv
camp
bind
domain
cbd
tightli
regul
divers
array
physiolog
process
muscl
contract
metabol
calcium
homeostasi
cell
apoptosi
immun
regul
cell
adhes
secret
regul
gene
express
mediat
camp
signal
initi
attribut
mainli
activ
two
primari
protein
famili
campdepend
protein
kinas
pka
cyclic
nucleotideactiv
channel
eg
hyperpolar
activ
cyclic
nucleotid
gate
channel
hcn
cyclic
nucleotid
gate
channel
cng
addit
campbind
protein
sinc
identifi
eg
popey
domain
contain
popdc
protein
cyclic
nucleotid
receptor
involv
sperm
function
cri
underscor
complex
camprel
signal
importantli
new
camp
receptor
discov
observ
campdepend
activ
small
gtpase
independ
pka
new
camp
receptor
known
exchang
protein
directli
activ
camp
epac
identifi
databas
screen
put
campbind
domain
two
isoform
epac
serv
guanin
exchang
factor
raslik
gtpase
primarili
broadli
express
eg
circulatori
excretori
reproduct
digest
system
wherea
abund
central
nervou
system
cn
pancrea
adren
gland
epac
regul
sever
critic
camprel
signal
pathway
includ
cardiac
calcium
homeostasi
vascular
remodel
tissu
homeostasi
regul
smooth
muscl
contract
insulin
secret
pancreat
cell
integrindepend
cell
adhes
neuron
excit
memori
consolid
hippocampu
thu
epac
inhibit
recogn
promis
therapeut
rout
wide
spectrum
diseas
includ
pancreat
cancer
breast
cancer
cardiac
hypertrophi
vascular
inflamm
alzheim
diseas
well
infect
eg
coronaviru
malaria
detail
physiolog
role
epac
subsequ
diseas
implic
refer
excel
review
publish
recent
year
given
critic
role
play
epac
multipl
patholog
sever
epacspecif
modul
screen
target
epac
protein
vide
infra
despit
wide
commerci
avail
seemingli
ubiquit
use
experiment
studi
sever
epac
inhibitor
molecular
basi
interact
epac
relat
mechan
action
current
fulli
understood
thu
limit
improv
exist
inhibitor
design
lead
optim
epactarget
drug
develop
anoth
notabl
impedi
drug
discoveri
develop
aris
hydrophob
natur
aforement
epac
inhibitor
make
suscept
format
colloid
aggreg
hydrophil
environ
aggreg
pronecompound
modul
specif
enzymesubstr
interact
due
nonspecif
enzymeaggreg
absorpt
ultim
modifi
enzym
activ
due
protein
misfoldingunfold
decreas
free
substrat
concentr
alter
effect
enzymesubstr
affin
andor
physic
separ
enzym
substrat
overal
phenomenon
nonspecif
enzym
inhibit
typic
refer
aggregationpron
inhibit
abi
notori
introduc
fals
posit
drug
screen
well
pose
sever
challeng
term
dosag
optim
drug
deliveri
physiolog
system
mani
aforement
epac
inhibitor
shown
great
therapeut
potenti
cellbas
vivo
model
despit
propens
form
colloid
aggreg
interestingli
sever
druglik
small
molecul
lead
compound
even
market
drug
show
aggregationpron
tendenc
particularli
micromolar
concentr
rais
question
specif
interact
enzym
enzymespecif
inhibitor
affect
latter
aggregationpron
tendenc
moreov
conclus
determin
ligandaggreg
involv
abi
bind
enzym
first
place
thu
comprehens
understand
mechan
abi
well
underli
specif
enzym
inhibitor
interact
critic
optim
epac
inhibitor
abi
ubiquit
sever
strategi
implement
counter
aggreg
format
mainli
exploit
sensit
ligand
aggreg
nonion
deterg
solubil
agent
deterg
triton
tx
human
bovin
serum
albumin
hsa
bsa
commonli
use
attenu
fals
posit
associ
abi
drug
screen
howev
introduc
ad
risk
gener
fals
neg
therefor
addit
understand
basi
abi
evalu
therapeut
potenti
epacspecif
inhibitor
esi
attenu
use
awar
mechan
abi
attenu
also
crucial
care
defin
consid
fals
posit
vs
fals
neg
balanc
object
review
summar
specif
interact
underli
epac
inhibit
two
promis
epacspecif
well
nonspecif
interact
result
colloid
aggreg
format
subsequ
aggregationbas
epac
inhibit
aqueou
system
manner
hope
provid
key
biophys
insight
epac
commun
evalu
inhibitori
potenti
current
commerci
avail
aggregationpron
epac
inhibitor
optim
exist
lead
compound
inform
futur
develop
epacspecif
inhibitor
addit
specif
mechan
abi
attenu
hsa
tx
also
briefli
discuss
context
epac
aim
advoc
conscienti
use
screen
esi
recommend
care
consider
fals
posit
vs
fals
neg
balanc
evalu
inhibitor
perform
presenc
compound
prior
discuss
specif
mechan
epac
inhibit
essenti
consid
architectur
epac
contribut
spatial
tempor
regul
campdepend
signal
epac
singlechain
monomer
protein
compos
two
region
ntermin
regulatori
region
rr
ctermin
catalyt
region
cr
figur
regulatori
region
consist
domain
target
epac
specif
subcellular
membran
site
camp
bind
domain
cbd
alloster
regul
epac
gef
activ
unlik
rr
includ
two
cbd
cbdb
homolog
figur
requir
campdepend
activ
cbda
nonessenti
epac
regul
may
serv
role
determin
intracellular
local
hand
organ
cr
isoform
similar
span
rasexchang
motif
rem
ra
associ
domain
ra
classic
homolog
domain
structur
element
catalyz
exchang
rap
gtpase
propag
camp
signal
import
note
epac
isoform
campdepend
activ
depend
rel
conform
conserv
ntermin
regulatori
region
rr
ctermin
catalyt
region
cr
epac
adopt
apo
inact
state
absenc
camp
cr
rr
sampl
primarili
close
conform
prevent
bind
cr
effect
inhibit
epac
gef
activ
cellular
camp
level
rise
campbind
conserv
cbd
rr
act
molecular
switch
allow
epac
assum
open
topolog
enabl
rap
access
cr
facilit
subsequ
guanin
nucleotid
exchang
figur
cbd
cbdb
homolog
evolutionarili
conserv
structur
element
trigger
aforement
conform
chang
therebi
act
key
modul
campdepend
signal
seen
figur
cbd
isoform
compos
subdomain
consist
six
punctuat
subdomain
span
eight
sheet
helic
ntermin
form
multipl
saltbridg
catalyt
region
close
topolog
interact
constitut
ionic
latch
il
block
rap
access
cr
maintain
constitut
inhibit
helic
form
conserv
structur
element
denot
found
cisregul
cbd
subdomain
hand
contain
two
main
region
campbind
name
basebind
region
bbr
span
well
phosphatebind
cassett
pbc
indispens
region
also
elicit
alloster
effect
campbind
cterminu
rr
hing
helix
serv
anoth
crucial
structur
element
epac
autoinhibit
absenc
camp
campdepend
epac
activ
figur
c
concert
movement
pbc
hing
helix
shift
protein
conform
open
close
topolog
therefor
underli
campdepend
epac
activ
absenc
camp
pbc
shift
outward
maintain
crucial
hydrophob
contact
conserv
leucin
pbc
phenylalanin
hing
helix
latter
also
adopt
conform
result
region
ctermin
hing
helix
also
known
lid
move
forc
rr
occlud
rapbind
site
cr
ie
epac
adopt
close
topolog
characterist
apo
inact
state
upon
campbind
pbc
shift
inward
cbd
equilibrium
shift
inact
state
activ
state
wherein
hing
helix
also
move
inward
maintain
hydrophob
contact
pbc
move
lid
allow
rap
protein
substrat
access
cr
open
topolog
figur
upon
remov
camp
pbc
hing
regain
orient
thermodynam
term
campbind
epac
inhibit
equilibria
coupl
form
fourstat
cycl
figur
provid
gener
framework
analyz
mechanismofact
epactarget
inhibitor
discuss
context
exist
two
ubiquit
express
campdepend
sensor
epac
pka
necessit
develop
select
pharmacolog
intervent
modul
discret
function
epac
vs
pka
select
obtain
first
time
structurebas
design
led
identif
camp
analog
function
activ
epac
pka
howev
contrast
epac
agonist
identifi
epac
select
antagonist
proven
much
challeng
cyclic
nucleotid
analogu
often
interfer
phosphodiesteras
activ
increas
cellular
cyclic
nucleotid
level
counter
intend
antagonist
effect
major
breakthrough
develop
epacspecif
small
molecul
inhibitor
report
develop
robust
epacbas
highthroughput
screen
ht
assay
effect
epac
ht
assay
util
fluoresc
camp
rapidli
identifi
hit
compet
camp
bind
implement
simpl
mixandread
assay
led
discoveri
panel
epac
specif
inhibitor
esi
start
druglik
compound
librari
two
compound
exclus
bind
interfac
cbda
cbdb
lock
enzym
autoinhibitori
conform
howev
major
identifi
esi
exhibit
panepac
activ
one
particular
compound
signific
research
focu
recent
year
use
function
fluorescencebas
nucleotid
exchang
assay
led
identif
anoth
epacspecif
inhibitor
screen
compound
name
unlik
competit
inhibitor
inhibit
epac
uncompetit
fashion
nformyl
compound
exist
interconvert
rotam
popul
insepar
e
z
mixtur
although
major
rotam
predomin
dmso
solut
shown
nmr
studi
crystallographi
studi
reveal
minor
rotam
exhibit
better
pack
stereochemistri
also
critic
importantli
r
potent
racem
exhibit
approxim
higher
select
structur
activ
relationship
studi
later
identifi
two
bromin
atom
phenyl
ring
formyl
group
critic
select
inhibit
subsequ
brown
et
al
identifi
noncompetit
inhibitor
virtual
screen
use
divers
compound
librari
chembridg
follow
ht
assay
use
isol
cbd
domain
led
identif
partial
agonist
arylsulfonamid
found
act
partial
agonist
appar
valu
maxim
activ
compar
camp
identif
epac
specif
inhibitor
via
ht
campaign
subsequ
medicin
chemistri
optim
provid
set
use
ligand
interrog
epac
mediat
cell
signal
particular
exhibit
excel
vivo
pharmacolog
toxicolog
profil
demonstr
therapeut
efficaci
variou
preclin
anim
model
develop
establish
epac
protein
promis
therapeut
target
henc
paramount
understand
mechan
underli
specif
nonspecif
interact
epac
modul
discuss
context
classic
uncompetit
inhibitor
specif
target
enzymesubstr
complex
oppos
freeenzym
thu
bind
competit
substrat
increas
substrat
concentr
amplifi
effect
inhibitor
furthermor
sole
recognit
enzym
substrat
complex
instead
free
enzym
increas
select
bind
rel
competit
inhibitor
uncompetit
inhibit
allow
simultan
optim
bind
specif
inhibitori
potenc
therefor
appeal
strategi
pharmacolog
biolog
intervent
upon
discoveri
figur
confirm
act
unconvent
uncompetit
inhibitor
unabl
appreci
inhibit
catalyt
activ
upon
remov
cbd
observ
suggest
bind
substratespecif
site
site
cr
instead
expect
classic
uncompetit
inhibit
wherea
classic
uncompetit
inhibitor
select
e
complex
nonclass
uncompetit
inhibitor
select
enzym
alloster
effector
complex
belong
latter
class
specif
inhibit
campbound
epac
rather
apo
epac
thu
form
camp
ternari
complex
figur
boulton
et
al
elucid
mechan
specif
inhibit
employ
divers
array
biomolecular
nmr
approach
supplement
variou
techniqu
gain
insight
natur
inhibitori
conform
within
camp
ternari
complex
nmr
chemic
shift
project
analys
chespa
perform
measur
degre
residuespecif
fraction
activ
x
x
valu
report
extent
residu
camp
ternari
complex
resembl
inact
apo
cbd
x
vs
activ
cbd
camp
complex
x
use
chespa
hing
helix
identifi
significantli
shift
toward
inactiv
x
togeth
adjac
helix
pbc
show
appreci
chang
compar
campbound
holo
activ
state
x
thu
bind
appear
shift
conform
epac
pbc
inhing
holo
activ
state
pbc
outhing
apo
inact
state
rather
seem
stabil
mix
intermedi
hing
conform
apolik
pbc
hololik
similar
conform
campbound
state
figur
support
notion
target
pbc
inhing
mix
intermedi
came
studi
interact
epac
variant
wherein
tryptophan
bulki
indol
group
steric
hinder
hydrophob
contact
pbc
hing
helix
result
variant
lock
pbc
hing
mix
conform
consist
predict
preferenti
bind
mix
state
fivefold
increas
bind
affin
observ
mutant
compar
wildtyp
final
neglig
bind
observ
ad
rpcamp
bound
bind
rpcamp
revert
enzym
complet
apo
inact
state
effect
destabil
mix
intermedi
neglig
bind
result
pbc
outhing
conform
serv
neg
control
valid
conclus
mechan
uncompetit
inhibit
involv
stabil
camp
ternari
complex
mix
intermedi
pbc
remain
hing
helix
adopt
conform
figur
inhibitori
mechan
somewhat
reminisc
stabil
mix
intermedi
pkg
camp
act
partial
agonist
kinas
addit
determin
alloster
effect
bind
boulton
et
al
also
went
defin
specif
bind
site
residu
involv
bind
initi
screen
use
chespa
base
nonlinear
project
vector
rel
refer
predict
simpl
cc
magnitud
map
residu
found
cluster
subdomain
interfac
find
independ
valid
satur
transfer
differ
std
experi
spectral
read
satur
inhibitor
formyl
reson
residu
significantli
higher
stdstr
ratio
overal
consist
exhibit
highest
degre
nonlinear
chespa
analysi
residu
involv
bind
thu
identifi
figur
use
paramagnet
relax
enhanc
pre
experi
call
slapstic
spinlabel
attach
protein
side
chain
tool
identifi
interact
compound
togeth
triangul
method
base
two
differ
spinlabel
locat
propos
bind
site
subdomain
interfac
independ
confirm
thu
specif
bind
site
conclud
span
least
four
key
residu
subdomain
interfac
rr
boulton
et
al
also
elucid
basi
select
vs
probe
subdomain
interfac
two
main
differ
found
two
isoform
latter
residu
especi
import
maintain
stabil
holo
activ
state
form
salt
bridg
interact
stabil
hing
helix
conform
therebi
reduc
popul
pbc
hing
intermedi
turn
likelihood
bind
lysineglutam
salt
bridg
found
basi
select
creat
mutant
observ
chemic
shift
chang
nhhsqc
spectra
perform
chespa
mutant
apo
campbound
state
exhibit
shift
toward
activ
hing
helix
show
significantli
reduc
chemic
shift
chang
upon
addit
confirm
ke
salt
bridg
result
stabil
hing
conform
major
determin
select
vs
although
promis
candid
therapeut
applic
due
uncompetit
inhibit
mechan
select
prone
aggreg
due
hydrophob
properti
may
limit
maximum
concentr
use
therapeut
applic
increas
suscept
nonspecif
effect
aggregationbas
inhibit
led
boulton
et
al
investig
nonspecif
interact
use
divers
techniqu
vari
degre
resolut
format
aggreg
vitro
studi
use
two
commonlyus
techniqu
name
dynam
light
scatter
dl
transmiss
electron
microscopi
tem
techniqu
submicromet
aggreg
observ
size
nm
accord
tem
howev
unlik
aggregationpron
inhibitor
aggreg
display
vari
irregular
morpholog
critic
aggreg
concentr
cac
key
determin
onset
nonspecif
interact
determin
monitor
point
deviat
linear
proport
increas
nmr
peak
intens
increas
inhibitor
concentr
valu
independ
valid
use
std
experi
std
signal
appear
concentr
format
high
molecular
weight
aggreg
establish
like
prototyp
hydrophob
drug
lead
form
larg
colloid
aggreg
micromolar
concentr
boulton
et
al
also
determin
mechan
abi
nonspecif
interact
oppos
commonli
observ
abi
phenomenon
protein
receptor
nonspecif
adsorb
onto
aggreg
surfac
aggreg
interact
directli
titrat
inhibitor
concentr
increas
significantli
beyond
cac
hnhsqc
crosspeak
shift
inact
state
activ
state
like
repres
dissoci
event
aggreg
recruit
camp
ternari
complex
bind
reduc
free
inhibitor
concentr
increas
total
inhibitor
concentr
need
aggreg
format
dissoci
event
occur
moreov
sinc
intens
loss
observ
hsqc
spectra
despit
aggreg
format
confirm
adsorb
form
high
molecular
weight
complex
aggreg
conclus
support
dl
experi
volum
profil
domin
nm
peak
deviat
significantli
upon
addit
inhibitor
concentr
cac
thu
classifi
typea
aggregationpron
inhibitor
form
inert
aggreg
adsorb
rather
interfer
specif
enzym
ligand
bind
act
sink
monomer
inhibitor
figur
reduc
free
inhibitor
concentr
nonspecif
interact
encompass
typea
abi
compet
specif
enzym
inhibitor
interact
thu
instead
standard
sigmoid
monoton
dose
respons
curv
bellshap
bimod
dose
respons
curv
maximum
therapeut
efficaci
occur
intermedi
concentr
expect
typea
inhibitor
aggregationbas
inhibit
involv
coupl
specif
bind
aggreg
equilibria
key
determin
interact
kd
specif
enzym
inhibitor
interact
cac
kd
requir
satur
enzym
specif
bind
site
cac
less
kd
enzym
fulli
satur
without
nonspecif
abi
effect
becom
signific
thu
gaug
applic
pharmacolog
intervent
epacrel
patholog
critic
determin
optim
therapeut
window
concentr
typea
inhibitor
along
figur
also
garner
signific
attent
recent
year
promis
epactarget
therapeut
aggregationpron
tendenc
exhibit
panepac
inhibitori
effect
vitro
vivo
studi
also
found
hinder
progress
pancreat
cancer
prevent
bacteri
invas
fatal
rickettsios
regul
tcell
mediat
suppress
immun
respons
despit
promis
result
high
concentr
perturb
campindepend
exchang
function
well
decreas
protein
stabil
suggest
condit
nonspecif
protein
denatur
howev
recent
comprehens
investig
zhu
et
al
structureact
relationship
sar
biophys
basi
action
demonstr
inde
competit
inhibitor
interact
specif
select
epac
figur
specif
interact
involv
inhibitori
mechan
elucid
use
divers
experiment
methodolog
first
moieti
figur
found
confer
specif
base
sar
analys
screen
seri
compound
core
structur
figur
vari
mono
disubstitut
chlorobenzen
ring
found
ring
interact
favor
therefor
highest
affin
competit
natur
epac
inhibit
independ
confirm
use
competit
assay
fluoresc
bodipygtp
epac
substrat
dosedepend
decreas
campmedi
gtpgdp
exchang
observ
addit
increas
camp
concentr
found
complet
revers
inhibitori
effect
consist
competit
inhibit
thu
conclud
interact
specif
competit
specif
inhibitor
appar
presenc
camp
previou
claim
caus
gener
protein
denatur
address
explain
gener
hydrophob
natur
result
format
colloid
aggreg
nonspecif
adsorb
protein
specif
epac
interact
independ
confirm
use
nhhsqc
spectra
exhibit
welldispers
peak
even
presenc
defin
characterist
fullyfold
intens
loss
select
residu
like
due
intermedi
exchang
howev
increas
inhibitor
concentr
beyond
result
linebroaden
almost
everi
hsqc
peak
beyond
detect
consist
nonspecif
adsorpt
protein
ligand
aggreg
format
high
molecular
weight
nmrinvis
speci
short
zhu
et
al
provid
consider
evid
interact
specif
epac
competit
inhibitor
highlight
potenti
limit
use
enzymat
assay
high
format
subsequ
aggregationbas
inhibit
build
zhu
et
al
work
mechan
nonspecif
epac
inhibit
also
determin
employ
biomolecular
nmr
techniqu
combin
biophys
techniqu
vari
degre
resolut
first
aggreg
format
document
confirm
use
dl
tem
show
much
like
also
form
submicromet
aggreg
aqueou
buffer
size
rang
nm
howev
aggreg
display
regular
circular
morpholog
similar
tradit
aggregationpron
compound
next
cac
determin
monitor
nmr
signal
line
width
conduct
std
experi
describ
earlier
thu
boulton
et
al
confirm
use
dl
tem
nmr
data
form
larg
colloid
aggreg
aqueou
solut
importantli
mechan
abi
epac
stark
contrast
wherea
form
inert
typea
aggreg
act
tradit
aggregationpron
inhibitor
form
aggreg
nonspecif
adsorb
protein
figur
evid
conclus
came
observ
nhhsqc
spectra
epac
titrat
concentr
cac
spectra
show
intens
loss
select
residu
like
due
intermedi
exchang
characterist
specif
bind
chemic
shift
perturb
use
calcul
kd
confirm
competit
bind
experi
fluoresc
label
camp
molecul
unlik
concentr
increas
well
cac
signal
loss
becam
significantli
pervas
pronounc
indic
interact
aggreg
find
corrobor
compar
dl
size
profil
addit
cac
reveal
signific
size
increas
latter
case
nm
diamet
apo
protein
nm
nm
also
significantli
smaller
nm
mean
diamet
aggreg
measur
like
populationweight
averag
free
aggregatebound
boulton
et
al
ultim
classifi
typeb
inhibitor
form
promiscu
colloid
aggreg
concentr
respect
cac
figur
although
differ
term
abi
mechan
typea
inhibitor
typeb
inhibitor
also
affect
enzym
substrat
bind
dynam
nonspecif
recruit
protein
submicromet
aggreg
case
possibl
unfold
protein
manner
typea
typeb
inhibitor
interfer
drug
screen
character
henc
respect
kd
cac
valu
must
determin
order
draw
conclus
potenc
specif
variou
paramet
later
determin
pharmacolog
valu
drug
lead
unlik
kd
cac
valu
known
respect
base
inform
assumpt
similar
kd
fulllength
epac
enzym
satur
maximum
inhibitori
potenc
concentr
greater
need
greater
cac
valu
howev
vivo
studi
effect
amelior
patholog
condit
exhibit
excel
bioavail
minim
toxic
concentr
less
ie
less
kd
base
observ
zhu
et
al
defin
therapeut
window
concentr
cac
consid
pharmacolog
effect
although
presenc
aggreg
within
cell
current
unclear
aggreg
hydrophob
drug
lead
caus
assay
interfer
vitro
limit
maximum
inhibitor
concentr
specif
interact
prevail
henc
divers
strategi
abi
attenu
develop
increas
specif
potenc
inhibitor
effect
aqueou
buffer
tradit
strategi
attenu
aggregationbas
inhibit
capitalis
aggreg
sensit
nonion
deterg
particularli
triton
tx
solubil
agent
human
bovin
serum
albumin
hsa
histor
approach
extens
util
elimin
nonspecif
bind
drug
screen
biochem
assay
abil
disrupt
abi
wellknown
promiscu
inhibitor
led
widespread
util
tool
diagnos
elimin
abi
almost
past
two
decad
howev
recent
studi
rais
concern
potenti
abi
attenu
disrupt
targetspecif
abiindepend
interact
exampl
hydrophob
core
tx
micel
may
recruit
sequest
free
hydrophob
inhibitor
even
tx
concentr
exceed
critic
micellar
concentr
cmc
possibl
coaggreg
hydrophob
compound
limit
abil
interact
intend
target
hsa
hand
transport
protein
interact
plethora
hydrophob
ligand
abil
potenti
interact
sequest
hydrophob
compound
screen
inhibitor
short
tx
hsa
compet
specif
enzym
inhibitor
bind
diminish
extent
specif
enzym
inhibit
introduc
potenti
falseneg
thu
import
understand
molecular
mechan
abi
attenu
tx
hsa
consid
fals
posit
vs
fals
neg
balanc
employ
compound
drug
screen
well
vitro
possibl
vivo
studi
understand
abi
attenu
especi
pertin
evalu
epactarget
strategi
major
current
known
epac
antagonist
small
hydrophob
compound
aggregationpron
aqueou
buffer
along
elucid
nonspecif
interact
underli
abi
epac
boulton
et
al
also
determin
mechan
abi
attenu
tx
hsa
well
natur
interact
epacspecif
inhibitor
first
tx
interact
monitor
nhhsqc
spectral
analysi
cmc
signific
chemic
shift
chang
line
broaden
observ
indic
tx
micel
inert
respect
facilit
enzym
unfold
next
interact
tx
esi
studi
variou
concentr
speci
concentr
significantli
cmc
tx
cac
formyl
moieti
found
interact
tx
facilit
format
larg
coaggreg
similarli
also
form
heterogen
coaggreg
detect
line
broaden
howev
base
dl
size
profil
size
morpholog
tx
tx
coaggreg
concentr
use
tx
coaggreg
popul
unstabl
heterogen
respect
size
wherea
tx
coaggreg
homogen
popul
thu
infer
tx
micel
capabl
incorpor
variou
hydrophob
inhibitor
effect
decreas
free
inhibitor
concentr
reduc
nonspecif
specif
enzym
inhibitor
interact
aforement
hypothesi
valid
boulton
et
al
displac
typea
bind
site
epaccdb
monitor
determin
effect
tx
specif
inhibitor
bind
base
nhhsqc
analysi
spectrum
previouslybound
shift
state
upon
addit
tx
confirm
hypothesi
tx
competit
extract
inhibitor
specif
esi
complex
addit
tx
previous
bound
typeb
inhibitor
concentr
cac
also
demonstr
effect
upon
confirm
tx
competit
interfer
specif
epac
esi
bind
protect
effect
tx
measur
prevent
recruit
aggreg
tx
concentr
greater
cmc
concentr
cac
nhhsqc
intens
loss
still
observ
despit
addit
tx
suggest
tx
addit
perceiv
protect
effect
recruit
nonspecif
adsorpt
aggreg
condit
howev
use
nmr
approach
incorpor
tx
aggreg
observ
suggest
rel
abund
two
speci
coaggreg
may
dictat
properti
specif
domin
speci
tx
micel
may
display
characterist
promiscu
contribut
nonspecif
abi
epac
overal
although
tx
widelyus
nonion
deterg
aggregationbas
drug
screen
introduc
sever
artifact
assay
result
act
competit
sink
free
inhibitor
therebi
introduc
fals
neg
well
incorpor
ligand
aggreg
invas
properti
figur
thu
use
tx
applic
requir
care
consider
minim
loss
specif
vs
nonspecif
interact
mechan
abi
attenu
hsa
also
examin
use
surfac
plasmon
reson
spr
boulton
et
al
confirm
hsa
disrupt
esi
aggreg
howev
nmr
analysi
also
demonstr
hsa
lead
competit
epac
bind
free
inhibitor
similar
tx
use
collect
nmr
fluoresc
probe
select
bind
hsa
specif
site
boulton
et
al
determin
competit
experi
bind
site
stoichiometri
affin
esi
hsa
analysi
reveal
esi
bind
hsa
affin
significantli
greater
epac
latter
find
particularli
disconcert
indic
higher
affin
hsa
would
significantli
shift
free
inhibitor
specif
epac
esi
bind
equilibrium
toward
hsa
bind
use
hsa
may
major
implic
assay
increas
likelihood
fals
neg
spr
dl
hnhsqc
nmr
peak
intens
use
determin
addit
hsa
inhibitor
concentr
cac
would
significantli
attenu
magnitud
aggreg
format
observ
case
although
hsa
increas
inhibitor
concentr
requir
reach
similar
fraction
satur
hsafre
condit
hsa
significantli
imped
aggreg
format
thu
promis
altern
strategi
tx
attenu
aggreg
drug
screen
fals
posit
vs
fals
neg
balanc
still
care
consid
interpret
result
experi
employ
hsa
review
explor
biophys
basi
specif
nonspecif
interact
two
prototyp
hydrophob
epac
use
solut
nmr
method
found
serv
nonclass
uncompetit
inhibitor
select
bind
mix
intermedi
campdepend
thermodynam
cycl
epac
activ
mix
intermedi
display
featur
campbound
holo
activ
state
pbc
conform
well
campunbound
apo
inact
state
hing
helix
conform
result
bind
captur
holo
inact
conform
stabil
close
topolog
effect
inhibit
enzym
specif
bind
site
subdomain
interfac
epac
campbind
domain
becom
avail
upon
camp
testament
inhibitori
mechan
uncompetit
respect
camp
alloster
effector
rather
substrat
addit
bind
specif
instead
due
key
residu
uniqu
former
isoform
uncompetit
specif
inhibit
upon
campbind
signal
mechan
tight
spatiotempor
regul
potent
highli
select
epactarget
therapi
may
use
slow
progress
multipl
patholog
track
spatial
tempor
camp
gradient
studi
aim
defin
vivo
therapeut
window
action
wherein
specif
bind
optim
nonspecif
effect
abi
neglig
addit
also
serv
model
design
new
class
epac
nonclass
uncompetit
inhibitor
target
mix
intermedi
therebi
maxim
inhibitori
specif
potenc
hand
second
inhibitor
discuss
panepac
competit
inhibitor
demonstr
signific
pharmacolog
effect
prevent
invas
metastasi
pancreat
breast
cancer
well
provid
protect
fatal
rickettsios
concentr
kd
interact
act
competit
inhibitor
thu
therapeut
window
action
defin
concentr
ideal
consid
pharmacolog
effect
howev
conduc
inhibitor
aggreg
subsequ
abi
due
hydrophob
natur
display
aggreg
aqueou
system
signific
impedi
reliabl
character
new
drug
lead
well
effect
administr
use
despit
similar
physic
properti
cac
aggreg
size
form
aggreg
distinct
morpholog
proteinbind
behavior
first
form
typea
inert
aggreg
interact
protein
decreas
likelihood
specif
enzym
inhibit
decreas
free
inhibitor
concentr
thu
typea
inhibitor
may
result
fals
neg
drug
screen
lead
bellshap
dose
respons
curv
contrast
form
invas
typeb
aggreg
nonspecif
adsorb
protein
perturb
specif
enzym
substrat
interact
caus
fals
posit
drug
screen
case
key
thermodynam
paramet
predict
balanc
specif
nonspecif
bind
inhibitor
cac
well
kd
specif
interact
cac
greater
kd
specif
enzym
inhibitor
interact
investig
cac
lower
kd
bind
equilibrium
shift
toward
selfassoci
aggreg
enzym
fulli
satur
inhibitor
latter
case
inhibitor
may
ideal
biolog
pharmacolog
applic
aqueou
system
tailor
use
inhibitor
divers
environ
also
review
mechan
abi
attenu
two
commonli
use
hsa
tx
remodel
invas
typeb
coaggreg
inert
typea
assembl
wherea
hsa
target
unbound
inhibitor
although
use
tool
counterscreen
diagnos
abi
tx
hsa
attenu
nonspecif
enzym
inhibitor
interact
compet
specif
enzym
inhibitor
interact
result
attenu
introduc
fals
neg
drug
screen
discount
potenti
viabl
drug
lead
thu
advoc
judici
use
compound
drug
screen
care
consider
fals
posit
vs
fals
neg
balanc
given
ubiqu
abi
given
current
identifi
esi
low
mw
hydrophob
compound
review
provid
mechanist
insight
appli
esi
well
thu
hope
relev
modifi
exist
esi
supplement
esi
abi
attenu
well
design
new
esi
modif
enhanc
solubl
decreas
aggreg
elucid
mechan
underli
specif
nonspecif
interact
epac
ligand
assist
use
epacmodul
tool
dissect
function
role
signal
pathway
also
design
next
gener
epacselect
antagonist
agonist
